Cynosure, a leader in medical aesthetics systems and technologies, announced it has appointed Nadav Tomer, an accomplished medical technology executive and former operating advisor to funds affiliated with Cynosure investor Clayton, Dubilier & Rice (CD&R), as Cynosure’s chief executive officer, effective May 1, 2023.
He succeeds Todd Tillemans, who will step down as chief executive officer and will work closely with Tomer to ensure a smooth transition, a statement said.
“Nadav has an incredibly strong track record of operational execution in the medical technology space, and we are thrilled to welcome him to Cynosure as CEO,” said Sandi Peterson, Cynosure’s board chairman. “Nadav brings decades of experience helping position global med-tech businesses for strong, profitable growth by advancing innovation, accelerating global commercialization and working with research and development teams to unleash their full potential. This will be invaluable as we leverage the strength of Cynosure’s talented team, global infrastructure and differentiated technology to continue bolstering the company’s competitive advantage. I am confident that Nadav is the right leader to shepherd Cynosure through its next chapter.”
“I am excited to join Cynosure at such an important inflection point for the medical aesthetics industry,” said Tomer. “I have been following Cynosure for some time, and I have been incredibly impressed by its innovative offerings, value proposition to its customers and world-class team. Each of these strengths is critical to long-term success and will help the company bolster the reach and performance of its global platform. Most importantly, I look forward to joining a mission-driven company that is redefining how medical aesthetics technology can empower the patients it serves to feel their best.”
Peterson continued, “On behalf of the entire board, I would like to thank Todd for his leadership over the past three years. He has been integral to building the strong foundation from which Cynosure is operating today, and we are grateful for his contributions. We wish Todd the best in his future endeavors.”
Nadav Tomer brings to Cynosure more than 22 years of highly relevant leadership experience, having overseen global P&Ls and led growth, transformation and turnaround initiatives for numerous global medical technology businesses. He has held senior leadership roles for a variety of Johnson & Johnson’s global businesses, including those focused on therapeutic areas such as diabetes care, spine, cardiology, endovascular, orthopedics and electrophysiology. In his most recent role with Johnson & Johnson, Tomer served as global president of the company’s $1.4 billion DePuy Synthes Spine franchise – one of the world’s most comprehensive spine portfolios – and drove global strategy, commercial execution, innovation and portfolio and brand management initiatives that stabilized the business from previous market share losses and set the business on a growth trajectory by tripling the pipeline value.
Since May 2022, Tomer has served as an operating advisor to funds affiliated with CD&R, Cynosure’s lead investor, where he has been responsible for supporting investment sourcing and advising the funds’ healthcare businesses. He is also an operating partner at Revival Healthcare Capital, an investment firm specializing in the medical device and diagnostic sectors of healthcare.
Tomer currently serves on the boards of directors of Augmedics and Vascular Graft Solutions. He is a graduate of the Advanced Management Program at Harvard Business School, holds a B.S. in Medicine from Ben-Gurion University of the Negev, and holds an M.B.A in Finance and New Ventures from Bar Ilan University.
HrNxt.com Newsdesk has researchers and writers with an excellent domain knowledge about the talent ecosystem, and the business environment. The team keeps a tab on the latest happenings in the ecosystem to bring most relevant news and insights for our readers. You can connect with our newsdesk at newsdesk@hrnxt.com.